|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
19
|
|
pubmed:dateCreated |
2007-10-2
|
|
pubmed:abstractText |
Nonsteroidal anti-inflammatory drugs mediate anticancer effects by modulating cyclooxygenase-2 (COX-2)-dependent and/or COX-2-independent mechanism(s); however, the toxicity issue is a concern with single agents at higher doses. In this study, we determined the combined effect of celecoxib, a COX-2 inhibitor, along with exisulind (sulindac sulfone/Aptosyn) at low doses in prostate cancer.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anticarcinogenic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin D1,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclooxygenase Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Methylnitrosourea,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Androgen,
http://linkedlifedata.com/resource/pubmed/chemical/Sulfonamides,
http://linkedlifedata.com/resource/pubmed/chemical/Sulindac,
http://linkedlifedata.com/resource/pubmed/chemical/Testosterone,
http://linkedlifedata.com/resource/pubmed/chemical/celecoxib,
http://linkedlifedata.com/resource/pubmed/chemical/sulindac sulfone
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
5965-73
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:17908994-Animals,
pubmed-meshheading:17908994-Anticarcinogenic Agents,
pubmed-meshheading:17908994-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:17908994-Cyclin D1,
pubmed-meshheading:17908994-Cyclooxygenase 2,
pubmed-meshheading:17908994-Cyclooxygenase Inhibitors,
pubmed-meshheading:17908994-Humans,
pubmed-meshheading:17908994-Male,
pubmed-meshheading:17908994-Methylnitrosourea,
pubmed-meshheading:17908994-Prostatic Neoplasms,
pubmed-meshheading:17908994-Pyrazoles,
pubmed-meshheading:17908994-Rats,
pubmed-meshheading:17908994-Rats, Wistar,
pubmed-meshheading:17908994-Receptor, Epidermal Growth Factor,
pubmed-meshheading:17908994-Receptors, Androgen,
pubmed-meshheading:17908994-Sulfonamides,
pubmed-meshheading:17908994-Sulindac,
pubmed-meshheading:17908994-Testosterone
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Exisulind in combination with celecoxib modulates epidermal growth factor receptor, cyclooxygenase-2, and cyclin D1 against prostate carcinogenesis: in vivo evidence.
|
|
pubmed:affiliation |
Department of Environmental Medicine, New York University School of Medicine, Tuxedo, New York 10987, USA. bhagavathi@env.med.nyu.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, N.I.H., Extramural
|
